chrisvoncsefalvay/vaers-outcomes huggingface dataset:
A non-serious, spontaneous report of positive nasopharyngeal culture for influenza A presented by febrile illness has been received from a physician concerning his daughter, subsequent to H1N1, Intranasal. Neither relevant medical history nor concomitant medications have been reported for this patient. The patient received second dose of H1N1, Intranasal on an unknown date in 2009 for an unknown indication. The patient had a positive nasopharyngeal culture for influenza A during a febrile illness six days after her second dose of intranasal H1N1 LAIV. The outcome of the reported event was unknown at the time of report.
Covid vaccine monitoring documentation. PT admitted 10/21/21 ? 11/3/21 documented as covid vaccine breakthrough. PT received Pfizer dose 1 4/6/21 lot ER8733 Pfizer dose 2 on 4/27/21 lot EW0161 .
She mentioned that she had COVID-19 as well; She mentioned that she had COVID-19 as well; This is a spontaneous report received from a contactable consumer (patient) via medical information team. A 53-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE Formulation: Solution for injection, lot number unknown, expiration date unknown), via an unspecified route of administration on 26Mar2021 at a single dose for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. Patient had the first dose of the vaccine on the 26Mar2021. She had "adverse reactions" that she'd like to report. She was asking that should she get the second dose? She mentioned that she had COVID-19 as well on an unspecified date in Mar2021. The outcome of the events was unknown.   Follow-up attempts are completed. No further information is expected.
Pt exp transient lightheadedness described as a drunk feeling 10 minutes p/vax w/Hep B vax;
Case initially received on 06/20/06. It was reported that a 19 year old man was vaccinated with one dose of inactivated poliomyelitis vaccine on 06/09/06. On 06/13/06 he developed headache, abdominal pain, slight diarrhea, experienced a syncope and was hospitalized. Examination revealed a splenomegaly and a cranial MRI showed a small area of demyelinization in the brain (left). A stool sample was positive for "salmonella". In this context of central demyelination and salmonella infection, it would have been relevant to have results of infectious check-up (Campylobacter pylori or enteroviruses) and medical history of the patient to fully assess the case.
Pt received immunizations in the NTR at approx 2:20 on 2/23/06. On the ride home, approx 10 min later, started to c/o a sore throat. Began coughing, wheezing and then vomited. Passed out, drooling and unresponsive. Swelling and hive to face, hive to trunk. No local reaction to sites.
Hemorrhagic placental cyst found on routine prenatal ultrasound 1/25/2022.  EDD: 3/23/2022
After receiving my vaccine I had started experiencing symptoms around 12 hours later  I had a bad cough and I had a fever of 101.The following day I felt very fatigued, and just could not do anything. My head had this continuous pounding and just felt very lightheaded .I also was experiencing nausea too the point where I could not eat much of anything. During the night I had the chills and this shaking that would not stop. I am currently still experiencing congestion, runny nose, and the chills. The I scheduled an appointment with my PCP and there I took a Covid Test and the results where negative. So they prescribed me the medicine for the nause I was experiencing due to the fact I have lost 6 pounds since the Vaccine.
Information regarding Flumist (2003-2004 Formula) (influenza virus vaccine, live intranasal (2003-2004 formula) nasal solution (frozen)) was received from a 26-year-old male who experienced blurred vision after receiving a dose on 12-Nov-2003. Medical history: Relevant medical history was not provided. Product details: Indication for Flumist (2003-2004 Formula) was immunization. Product was administered on 12-Nov-2003. Dose regimen was 1 dose 1 time per day (nasal). Concomitant therapy: Concomitant medications were not reported. Event details: The patient experienced blurred vision (vision blurred) after receiving a dose on 12-Nov-2003. No additional information was available at the time of this report.
As 4th Anthrax vaccine was being administered in posterior upper right arm, pt noted Plexion contracture of both 4th and 5th fingers (lasting seconds) followed by sensation of coldness of hypothermal eminence. This was followed by tingling paresthesias lasting approximately 1 hour and then followed by extreme soreness of entire arm.
Pain jaw; Pain behind ear; Palpations; itchiness; Rash; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN JAW (Pain jaw), EAR PAIN (Pain behind ear), HEART RATE INCREASED (Palpations), PRURITUS (itchiness) and RASH (Rash) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 immunisation.     Concomitant products included LEVOTHYROXINE, ALLOPURINOL (ZYLOPRIM), FUROSEMIDE, DONEPEZIL HYDROCHLORIDE (ARICEPT), LOSARTAN POTASSIUM, SIMVASTATIN and ACETYLSALICYLIC ACID (ASPIRIN (E.C.)) for an unknown indication.   On 08-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 12-Mar-2021, the patient experienced PRURITUS (itchiness) and RASH (Rash). On 13-Mar-2021, the patient experienced PAIN IN JAW (Pain jaw), EAR PAIN (Pain behind ear) and HEART RATE INCREASED (Palpations). The patient was treated with LORATADINE, PSEUDOEPHEDRINE SULFATE (CLARITIN D 12 HOUR) at an unspecified dose and frequency. On 13-Mar-2021, PRURITUS (itchiness) and RASH (Rash) had resolved. At the time of the report, PAIN IN JAW (Pain jaw), EAR PAIN (Pain behind ear) and HEART RATE INCREASED (Palpations) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 13-Mar-2021, Heart rate: palpations (High) Palpations.         Action taken with mRNA-1273 in response to the events was not Applicable.
Fever of 100.5 for 3 days; Nauseous for 24 hours; Headache to the point couldnt get out of bed; This is a spontaneous report from a non-contactable consumer, the patient. A 34-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the right arm on 07Jul2021 at 16:00 (at the age of 34-years-old), as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the right arm on 16Jun2021 at 16:00 (at the age of 34-years-old), as a single dose for COVID-19 immunisation. On 08Jul2021, the patient experienced fever of 100.5 for three days, nauseous for 24 hours and headache to the point couldn't get out of bed. The events did not result in doctor or other healthcare professional office or clinic visit,  emergency room or department or urgent care. Therapeutic measures were not taken as a result of the events. On 08Jul2021, the patient underwent lab test and procedure which included body temperature and the result was shown as 100.5 (units unspecified). The clinical outcome of the events fever of 100.5 for 3 days was resolved on 10Jul2021. The clinical outcome of the event nauseous for 24 hours was recovered on 09Jul2021. The clinical outcome of the event headache to the point couldn't get out of bed was unknown at the time of this report.    No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Epistaxis; This is a non-serious spontaneous case, initially received from a physician on 20-May-2019, concerning a male elderly patient of unspecified age.   On an unspecified date, the patient was administered INN Flu Vaccine Seasonal (influenza vaccine, influenza virus vaccine polyvalent; dose, route of administration, anatomical location, batch number, frequency, expiry date, trade name and manufacturer: not reported] for an unknown indication.  On an unspecified date, after vaccination, the patient consistently experienced epistaxis for the last 3 years.  The outcome of the event was not reported.  This case is linked to 201903515 (same patient).; Reporter's Comments: A male patient of unspecified age, consistently experienced epistaxis for the last 3 years on an unspecified period of time after administration of INN Flu Vaccine Seasonal. The causality of the event was unassessable due to lack of information regarding the vaccination date and onset latency  of the event.
Diffuse joint swelling began on 7/2/98. Pt with frank arthritis and joint swelling/effusion. Joint fluid sterile. Resolved with PT/NSAIDS. Hospitalized X 7 days. Still disabled but improving.
booster vaccine 14 days ago / I have come down with shingles; This case was reported by a other health professional and described the occurrence of shingles in a male patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, less than 2 weeks after receiving Shingrix, the patient experienced shingles. On an unknown date, the outcome of the shingles was unknown.   The reporter considered the shingles to be possibly related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. 14 days ago, the patient received booster vaccine. The patient experienced shingles that believe might have come from the vaccine. The patient had been to the emergency room twice in the past week and they can't discover anything related to this pain. The patient was hoping you might have anyone come down with similar maladies. This case has been linked with case US2020AMR181691 reported by the same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020AMR181691:same reporter, wife case
2 wks p/DTP/HIB pt devel ptosis of rt eye; seen by MD who attributed the ptosis to DTP rxn; no other neurological defecits noted; ptosis resolved p/ 2 wks;
localized itching at injection site. Benadryl 50mg capsules given.  itching decreased- got better.
This spontaneous report was received from a medical assistant concerning a 14-year-old patient of an unknown gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On 04-APR-2016, the patient was vaccinated with an improperly stored dose of GARDASIL 9 (lot number: L026602, expiration date 19-OCT-2017, dose, dose number, anatomical location and route of administration were not provided). The vaccine underwent temperature excursion of either +1 or -1 degree Celsius for 255.5 total cumulative hours, which was detected by a data logger. There was no previous temperature excursion. No adverse effects were reported. This is one of several reports received from the same reporter. Additional information is not expected as all the data was already obtained.
Information has been received from a pharmacist concerning a 66 year old female with not known allergies or pertinent medical history who on 07-APR-2008 was vaccinated SQ with a dose of ZOSTAVAX (Merck) 0.65 ml (Lot # 659761/0157X). Concomitant therapy included ALLEGRA and Prevacor. The pharmacist reported that the patient who received ZOSTAVAX (Merck) developed welts at the panty line, bra line, and near the neck that manifest after taking an evening shower and subside by the morning. The patient noticed the welts first appearing about two weeks on approximately 21-APR-2008 after receiving the ZOSTAVAX (Merck) injection. The welts persists although less intense. No other symptoms or treatment reported. The patient's physician did not attribute the welts to ZOSTAVAX (Merck). The patient sought medical attention, he was seen in the office visit. There was no product quality complaint. Additional information has been requested.
Monday night was up all night with severe cramps & began vomiting; Monday night was up all night with severe cramps & began vomiting; This is spontaneous report from a contactable consumer. A 14-years-old (Adolescent 12-17 Years) non pregnant female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for Injection, Batch/Lot number: EW0173) intramuscularly, administered in right arm, on 13May2021 (Thursday) at 16:00 (at the age of 14-year-old), as single dose for covid-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient did not receive any other medications within 2 weeks of vaccination. The patient had no known allergies. It was reported that, patient started period on 15May2021, Friday night on schedule. On 17May2021, at 10:00 AM, the patient had started experiencing severe cramps on Monday at school. It was reported that patient never had cramps before and has been having periods for 14 months. It was reported that Monday night was up all night with severe cramps and began vomiting. And still experienced cramping on Tuesday morning with vomiting. No treatment was received. The outcome of the menstrual cramps severe was resolved on 18May2021. The outcome of the event vomiting was not recovered.  Follow-up attempts are completed. No further information is expected.
Friday night headache, fever 102, nauseated, dizzy swollen (L) arm 7 cm x 5.5 cm induration 2 x 2.5 cm.
No adverse event; child received bivalent booster for adults; child received bivalent booster for adults; This spontaneous case was reported by a pharmacist and describes the occurrence of INCORRECT DOSE ADMINISTERED (child received bivalent booster for adults), PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (child received bivalent booster for adults) and NO ADVERSE EVENT (No adverse event) in a 3-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.  On 23-Sep-2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 23-Sep-2022, the patient experienced INCORRECT DOSE ADMINISTERED (child received bivalent booster for adults) and PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (child received bivalent booster for adults). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, INCORRECT DOSE ADMINISTERED (child received bivalent booster for adults), PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (child received bivalent booster for adults) and NO ADVERSE EVENT (No adverse event) outcome was unknown.     For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for INCORRECT DOSE ADMINISTERED (child received bivalent booster for adults) and PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (child received bivalent booster for adults).    No concomitant medications were reported.  The reporter wanted to know what type of adverse reactions should be expected.  No treatment medications were reported.  Reporter did not allow further contact
4/28/2021   Mswas observed post Covid-19 immunization for 15 minutes .  During the observation period, she experienced an adverse reaction with the following symptoms:  dizziness.   Assessment : Time of assessment 1207. Alert and oriented and Anxious.   Actions taken: .  Vitals sign taken  VAERS form completed Apple juice given VS at 1207- BP- 146/74, P- 60, O2- 100 %, 1222- recheck VS, BP- 154/71, P- 61, O2- 100 %     Medications administered: No medication administered.   Disposition: Reports no further symptoms of adverse reaction after observation for 30 minutes. Discharged home. The Patient was provided with Vaccine Information Sheet and instruction to access the V-Safe system.      Immunizations Administered    Name Date Dose VIS Date Route   Pfizer COVID-19 Vaccine 4/28/2021 11:46 AM 0.3 mL 2/25/2020 Intramuscular   Manufacturer: Pfizer, Inc   Lot: ER8736   NDC: 59267-1000-2
Arm itches; This case was reported by a consumer via interactive digital media and described the occurrence of itchy upper limbs in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, 5 days after receiving Shingles vaccine, the patient experienced itchy upper limbs. On an unknown date, the outcome of the itchy upper limbs was unknown.   It was unknown if the reporter considered the itchy upper limbs to be related to Shingles vaccine.     Additional Information: GSK Receipt date: 28-Jan-2023. Reporter's Comment: This case was reported by a consumer via interactive digital media. The reporter stated that it's been 5 days since vaccine and arm itches. Additional Supportive Information: Follow-up would not possible as no contact details were available. Note: As it was not clear if event occurred after 5 days or its been 5 days since vaccination. Conservatively 5 days were captured as latency based upon discrepant information in narrative
This spontaneous report as received from a physician refers to a 4 year old patient of an unknown gender. On an unknown date the patient was vaccinated with a third dose of VAQTA, (dose, route, lot number and expiration date not reported). No adverse effect reported. Additional information has been requested.
EXTREME muscle aches and fatigue. Started the next morning. Time and rest have been the only thing that is working. Still ongoing. Doing better, just not back to "normal "
Other than the expected 'flu-like' symptoms, which were severe, I have shooting pain and severely restricted range of motion ever since the shot. It is my sense that I was improperly inoculated outside the deltoid muscle, hitting the axillary nerve. The symptoms came on almost immediately, though (since it's a while ago) I cannot be reliably sure of the time. The pharmacist injecting me was very scattered, in my opinion, and perhaps tired from a long day of immunization. My sense is that she failed to properly landmark my arm. I am a short-stature woman with good muscle tone, if that helps. I am seeking medical evaluation on 4/9 and, likely, will start physical therapy to regain range of motion, which is disabling.
I started having symptoms 24 hours after injection. My symptoms included fever, body chills, increased swelling to injection site with hardness and burning, throbbing and painful; my lymph nodes was swollen; swelling occurring across my chest; my left arm, underarm and chest muscle was tender to touch; I had a dry cough during  inhaling but no shortness of breath. I was extremely fatigue .
Felt sick after vaccine then had chest pain heart pain then it traveled up to brain and caused a form of brain damage. was hositalized for mental illness.
left eye chalazion/I had a reaction on my left top eye lid and pimple emrgedstill have 2 chalazions on left eye; low grade fever,; This spontaneous case was reported by a consumer and describes the occurrence of CHALAZION (left eye chalazion/I had a reaction on my left top eye lid and pimple emrgedstill have 2 chalazions on left eye) and PYREXIA (low grade fever,) in a 56-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037A21B) for COVID-19 vaccination.     Concurrent medical conditions included Asthma. Concomitant products included ATORVASTATIN and FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE (WIXELA INHUB) for an unknown indication.   On 15-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form(s). On 15-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 15-Apr-2021, the patient experienced PYREXIA (low grade fever,). On 21-Apr-2021, the patient experienced CHALAZION (left eye chalazion/I had a reaction on my left top eye lid and pimple emrgedstill have 2 chalazions on left eye). The patient was treated with CALCIUM at an unspecified dose and frequency. At the time of the report, CHALAZION (left eye chalazion/I had a reaction on my left top eye lid and pimple emrgedstill have 2 chalazions on left eye) and PYREXIA (low grade fever,) outcome was unknown.            This case was linked to MOD-2021-086442 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 27-May-2021: Treatment drug and concomitant drugs were added along with other relevant history
Swelling and redness in face, rash on right forearm, face and right ear.
Encephalitis, brain swollen, dizzy, confused, tired, headache, swollen face and eyes.
My tongue started swelling. It did not get bad but I could feel it. Then my left eyelid felt like it had something in it so I believe it was also slight swelling. I was driving home. Both of these issues went away completely about 2 hours after they received vaccine.
Woke up at 8:00 AM 12/11/09 - when reading words were blurred and continue to have blurred vision in both eyes.
In short, I had one episode in which I fainted and another few episodes in which I felt shortness of breath, abnormal heartbeat, and the feeling of near fainting. One of the near fainting episodes was at work where I had to be picked up off of the floor in my office and brought by ambulance to the ER. Tests were run and found nothing. Then I was referred to a cardiologist. He wrote the following note: Patient comes in with 2 episodes of syncope. The 1st occurred several weeks ago while he was traveling, he had drunk more than usual at that time had smelled marijuana which caused become lightheaded and eventually passed out.  The 2nd episode occurred yesterday, he was at work and noted the onset of palpitations lightheadedness and passed out.  He was evaluated at Hospital where an EKG, and extensive laboratory evaluation was unremarkable.  This included a D-dimer, BNP, troponin and TSH. He does not have a history of heart problems, but has had hypertension for many years.  His blood pressure has been well controlled.  He has not been on an unusual diet.  His drug screen was negative. Family history negative for sudden death, heart problems. However, since probably July or August of 2021, I have not had any of the above mentioned symptoms. I have had unusual intense fatigue after exercise a few times but that has not occurred in the past couple of months.